Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …

Pituitary adenomas (PAs) are neoplasms derived from the endocrine cells of the anterior
pituitary gland. Most frequently, they are benign tumors, but may sometimes display an …

Objective To describe clinical and pathological characteristics and treatment outcomes in a
large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design …

Objective After temozolomide failure, no evidence-based treatment is available for pituitary
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior,
due to their clinical course, local invasive growth, resistance to conventional therapies and …

Immunotherapy has revolutionised the treatment of oncological patients, but its application
in various endocrine tumours is rather limited and is mainly used when conventional …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …